Genetics Generation Advancement Corp. Stock
Equities
4160
TW0004160007
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
67.7 TWD | -2.03% | +21.98% | +74.04% |
Sales 2022 | 548M 16.99M | Sales 2023 | 592M 18.37M | Capitalization | 988M 30.64M |
---|---|---|---|---|---|
Net income 2022 | 25M 775K | Net income 2023 | 28M 868K | EV / Sales 2022 | 0.75 x |
Net cash position 2022 | 255M 7.91M | Net cash position 2023 | 266M 8.24M | EV / Sales 2023 | 1.22 x |
P/E ratio 2022 |
26.1
x | P/E ratio 2023 |
34.7
x | Employees | 104 |
Yield 2022 |
1.74% | Yield 2023 |
1.31% | Free-Float | 58.95% |
1 day | -2.03% | ||
1 week | +21.98% | ||
Current month | +35.94% | ||
1 month | +34.06% | ||
3 months | +58.18% | ||
6 months | +67.57% | ||
Current year | +74.04% |
Managers | Title | Age | Since |
---|---|---|---|
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Tai Sheng Chang
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fang Chun Huang
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yue Jen Huang
BRD | Director/Board Member | - | 20-06-09 |
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Wen Cheng Chang
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 67.7 | -2.03% | 645,131 |
24-05-22 | 69.1 | +1.62% | 1,246,688 |
24-05-21 | 68 | +1.34% | 1,037,005 |
24-05-20 | 67.1 | +10.00% | 1,453,480 |
24-05-17 | 61 | +9.91% | 1,640,480 |
End-of-day quote Taipei Exchange, May 22, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+74.04% | 53.31M | |
-26.90% | 9.98B | |
-16.78% | 2.75B | |
-17.50% | 2.07B | |
-24.25% | 1.59B | |
+64.58% | 1.43B | |
+31.92% | 824M | |
-5.02% | 733M | |
-29.59% | 508M | |
+0.20% | 296M |
- Stock Market
- Equities
- 4160 Stock